Pediatric Endocrinology · Developmental delay, epilepsy, and neonatal diabetes syndrome

Standard of Care: The Sulfonylurea Transition

At a Glance

Some children with DEND syndrome can switch from insulin to a high-dose oral medicine such as glyburide under specialist supervision; the exact gene change affects success, and seizure or developmental improvements are not guaranteed.

For individuals with DEND or iDEND syndrome whose genetic testing confirms a pathogenic variant in KCNJ11 or ABCC8, a major part of care is determining if they can transition from insulin injections to an oral medication called a sulfonylurea (most commonly glyburide, also known in many settings as glibenclamide) ^[1]. This medication works at the source of the KATP channel defect to help the body start producing its own insulin ^[2].

How Sulfonylureas Act on the “Broken Gate”

As covered in the genetics page, DEND is caused by KATP channels (gates) that are stuck open ^[3]. Sulfonylureas act like a physical “key” that fits into the SUR1 part of the gate ^[4]. When the medication binds to this spot, it can force the gate to close.

In the pancreas, closing these gates allows the pancreas to release the insulin it has been making, managing blood sugar naturally ^[5]. Because these same gates are also in the brain, the medication may sometimes help stabilize the electrical activity that contributes to seizures and developmental delays ^[6]^[7].

The Transition Process: A Supervised Titration

Moving from insulin to a sulfonylurea is a precise medical process called titration. It must be directed by an experienced pediatric endocrine team, often with intensive glucose monitoring and sometimes inpatient supervision.
Never independently adjust doses or stop insulin on your own.

The Escalation: Because the “open gates” in DEND are very stubborn, treating this syndrome often requires much higher doses of sulfonylureas than standard adult diabetes treatments ^[8]. Doses are increased carefully over days or weeks ^[9].
Administration Safety: Safe measurement requires an exact formulation and concentration. Always use an oral syringe for liquid medications (never household spoons). If using tablets, confirm with the pharmacist whether a particular tablet may be crushed or if a compounded liquid is required ^[10].
Monitoring: Your team will likely use a Continuous Glucose Monitor (CGM) alongside frequent finger-stick checks to watch blood sugar trends in real-time and avoid prolonged hypoglycemia ^[11]^[12].

Why the Specific Mutation Matters

The success of the transition depends heavily on the specific genetic mutation identified and the child’s age and clinical history ^[13].

Response Rates: In appropriately selected cases within large study cohorts, around 88–91% of children with KCNJ11 or ABCC8 mutations transitioned off insulin successfully ^[13]^[8].
Variant Sensitivity: Some mutations are less responsive. Depending on residual channel function and variant type, some individuals must remain on insulin entirely, or use a combination of insulin and oral medication ^[13].

Neurological Outcomes: What to Expect

A major hope of sulfonylurea treatment is its potential impact on the brain ^[6].

Observational Benefits: Studies have shown that some children experience a reduction in seizures and improvements in hypotonia (low muscle tone) and motor skills ^[7]. Earlier treatment is observationally associated with greater benefit ^[7].
No Guarantees: It is critical to know that neurological benefit is not guaranteed. Response is person-specific; established developmental differences frequently persist, and some individuals continue to require anti-seizure medications and extensive developmental support despite excellent diabetes control ^[14]^[15].

The goal of this transition is to provide the most stable metabolic environment possible ^[1]. Success is measured by overall well-being, stable blood sugars, and individualized progress.

Common questions in this guide

Can a child with DEND syndrome switch from insulin to an oral medicine?

Many children with a KCNJ11 or ABCC8 genetic change can transition from insulin to a sulfonylurea such as glyburide, but the exact change, age, and clinical history matter. Some children do not respond fully and may need insulin alone or a combination of insulin and oral medicine. The transition should be planned and supervised by an experienced pediatric endocrine team.

How does glyburide help treat DEND syndrome?

Glyburide, also called glibenclamide, helps close the cell channels that are stuck open in DEND syndrome. This can allow the pancreas to release insulin it has already made and may also stabilize electrical activity in the brain. Brain-related benefits, such as fewer seizures, are possible but not guaranteed.

What happens during the transition from insulin to a sulfonylurea?

The medical team gradually increases the sulfonylurea dose over days or weeks while monitoring blood sugar closely. Monitoring may include a continuous glucose monitor, finger-stick checks, ketone checks, and sometimes a hospital stay. Caregivers should never stop insulin or change doses without instructions from the treatment team.

How likely is it that a child with DEND syndrome can stop insulin?

In selected study groups, about 88% to 91% of children with KCNJ11 or ABCC8 changes transitioned off insulin successfully. This rate does not apply to every child because some genetic changes respond less well. A child may need insulin alone or both insulin and a sulfonylurea.

Can sulfonylureas improve seizures or developmental problems in DEND syndrome?

Some children have fewer seizures or improvements in low muscle tone and movement after treatment, and earlier treatment has been associated with greater benefit. However, neurological improvement is not guaranteed, and established developmental differences may persist. Some children still need anti-seizure medicine and developmental support.

How should liquid glyburide be measured safely?

Use an oral syringe to measure liquid glyburide or another liquid sulfonylurea; household spoons are not accurate enough. Ask the pharmacist whether tablets can be crushed or whether a compounded liquid is needed. Use the exact formulation and concentration prescribed by the care team.

Get notified when new evidence is published on DEND syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (15)

1
The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study.
De Franco E, Flanagan SE, Houghton JA, et al.
Lancet (London, England) 2015; (386(9997)):957-63.
PMID: 26231457
2
New insights into KATP channel gene mutations and neonatal diabetes mellitus.
Pipatpolkai T, Usher S, Stansfeld PJ, Ashcroft FM
Nature reviews. Endocrinology 2020; (16(7)):378-393 doi:10.1038/s41574-020-0351-y.
PMID: 32376986
3
ATP-Sensitive Potassium Channels in Hyperinsulinism and Type 2 Diabetes: Inconvenient Paradox or New Paradigm?
Nichols CG, York NW, Remedi MS
Diabetes 2022; (71(3)):367-375 doi:10.2337/db21-0755.
PMID: 35196393
4
Structural Insights into the Inhibitory Mechanism of Insulin Secretagogues on the Pancreatic ATP-Sensitive Potassium Channel.
Wu JX, Ding D, Wang M, Chen L
Biochemistry 2020; (59(1)):18-25 doi:10.1021/acs.biochem.9b00692.
PMID: 31566370
5
Kir6.2 channel activity is regulated by interaction of transmembrane domains 1 and 2 through I167 in the bundle-crossing gate.
Kawashima R, Meller C, Suzuki M, et al.
Physiological reports 2025; (13(15)):e70481 doi:10.14814/phy2.70481.
PMID: 40746251
6
Production and purification of ATP-sensitive potassium channel particles for cryo-electron microscopy.
Driggers CM, Shyng SL
Methods in enzymology 2021; (653()):121-150 doi:10.1016/bs.mie.2021.02.008.
PMID: 34099169
7
Sulfonylurea for improving neurological features in neonatal diabetes: A systematic review and meta-analyses.
de Gouveia Buff Passone C, Giani E, Vaivre-Douret L, et al.
Pediatric diabetes 2022; (23(6)):675-692 doi:10.1111/pedi.13376.
PMID: 35657808
8
Neonatal diabetes due to potassium channel mutation: Response to sulfonylurea according to the genotype.
Garcin L, Mericq V, Fauret-Amsellem AL, et al.
Pediatric diabetes 2020; (21(6)):932-941 doi:10.1111/pedi.13041.
PMID: 32418263
9
ABCC8-related maturity-onset diabetes of the young: switching from insulin to sulphonylurea therapy: how long do we need for a good metabolic control?
Evin F, Işık E, Onay H, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2023; (36(6)):592-597 doi:10.1515/jpem-2022-0642.
PMID: 37071846
10
Safety and Effectiveness of Oral Glyburide Suspension in Neonatal Diabetes Mellitus: French Retrospective Cohort Study.
Ben Rhaiem I, Beltrand J, Vermillac G, et al.
Journal of the Endocrine Society 2025; (9(7)):bvaf083 doi:10.1210/jendso/bvaf083.
PMID: 40469835
11
Use of a long-term continuous glucose monitor for predicting sulfonylurea dose in patients with neonatal diabetes mellitus: a case series.
Tagawa K, Matsui K, Tsukamura A, et al.
Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology 2024; (33(3)):131-138 doi:10.1297/cpe.2023-0062.
PMID: 38993723
12
The role of intermittent continuous glucose monitoring in a successful outpatient transition from insulin to glibenclamide in a patient with transient neonatal diabetes.
Lyra A, Ferreira FR, Moisés RCS, et al.
Archives of endocrinology and metabolism 2022; (66(3)):429-435.
PMID: 35612844
13
Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.
Babiker T, Vedovato N, Patel K, et al.
Diabetologia 2016; (59(6)):1162-6 doi:10.1007/s00125-016-3921-8.
PMID: 27033559
14
Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
Bowman P, Sulen Å, Barbetti F, et al.
The lancet. Diabetes & endocrinology 2018; (6(8)):637-646 doi:10.1016/S2213-8587(18)30106-2.
PMID: 29880308
15
Cognitive, Neurological, and Behavioral Features in Adults With KCNJ11 Neonatal Diabetes.
Bowman P, Day J, Torrens L, et al.
Diabetes care 2019; (42(2)):215-224 doi:10.2337/dc18-1060.
PMID: 30377186

This page is for informational purposes only and does not constitute medical advice about DEND syndrome. Do not change insulin or sulfonylurea doses without guidance from your child's pediatric endocrine team.